> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CBER Plans to Normalize Operations in 2023
- URL: https://www.fdaweb.com/cber-plans-to-normalize-operations-in-2023/
- Published: 2022-06-10T12:00:00.000Z
- Updated: 2026-09-14T17:48:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5152039

CBER has updated its prioritization schedule for the remainder of 2022 to account for Covid-19-related work. For the remainder of the year, the Center will continue to prioritize resources for Covid-19 regulatory work over non-Covid work, as needed. “As we enter calendar year 2023, we plan to resume normal operations,” an [agency notice](https://www.fda.gov/media/136501/download?ref=fdaweb.com) says.

Regarding CBER in-person meetings with industry, the Center says it has no immediate intention of moving away from its ongoing virtual format. “CBER will continue to assess the feasibility of holding in-person meetings at FDA facilities,” the notice says, adding that industry should monitor the CBER Web site for updates on future meeting formats.

During the pandemic, CBER paused certain lot release activities, including receiving biological product samples or protocols in physical form (paper or CD-ROM) until further notice. “Applicants should monitor the CBER Web site for updates regarding lot release activities,” the notice says.

It covers additional Covid-related activities, such as electronic document submissions, and inquiries about single-patient INDs, among other topics.